Bottom Article Ad

Monday, March 6, 2023

Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size, Share, Growth, Report and Forecast 2023-2031

The ‘Global Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Share, Size, Report and Forecast 2023-2031’ by Expert Market Research gives an extensive outlook of the global Bruton’s tyrosine kinase (BTK) inhibitors market, assessing the market on the basis of its segments like type, drug, application, distribution channel, and major regions.

The report studies the latest updates in the market, along with their impact across the market. It also analysis the market demand, together with its price and demand indicators. The report also tracks the market on the bases of SWOT and Porter’s Five Forces Models.

Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size, Share, Price, Growth, Trends, Industry Report, Key Player, Major Segments and Forecast

The key highlights of the report include:

Market Overview (2016-2031)

  • Historical Market Size (2022): USD 559 billion
  • Forecast CAGR (2023-2031): 8.2%

The growth of the global Bruton’s tyrosine kinase (BTK) inhibitors market can be attributed to increased initiatives by various governments to create awareness regarding BKT inhibitors among the general population. Increasing investments in healthcare infrastructure and research and development sector alongside prevailing risk of mantle cell lymphoma is predicted to have a positive impact on the growth of the market. The projected increase in development of advanced technology is expected to provide lucrative opportunities to the market.

Get a Free Sample Report with Table of Contents@

The market for Bruton tyrosine kinase inhibitors is expected to grow at an exponential rate in the coming years as therapeutic and medical sectors develop. These inhibitors have a broad consumer base and are expected to further grow in the future due to the market’s rapid expansion. Initiatives to spread awareness about various modes of treatment is further expected to boost the global Bruton’s tyrosine kinase (BTK) inhibitors market growth.

This growing awareness alongside rise in research and development expenditure by biopharmaceutical companies is set to offer great advancements to the BKT inhibitors market. However, the lack of availability of qualified medical professionals and limited infrastructure is expected to pose as a challenge for the BKT inhibitors market in developing countries.

Bruton’s Tyrosine Kinase (BTK) Inhibitors Industry Definition and Major Segments

A Bruton tyrosine kinase (BKT) inhibitor regulates B cell proliferation, differentiation, signalling, and growth by targeting B cell receptors. BKT inhibitors fall under the category of non-receptor tyrosine kinase inhibitors. Their primary function is the inhibition of the enzyme BKT, this function is essential for receptor signalling pathway of B cells.

Read Full Report with Table of Contents@

On the basis of type, the market is bifurcated into:

  • First Generation
  • Second Generation

Based on drug, the market is divided into:

  • Imbruvica
  • Calquence
  • Brukinsa

On the basis of application, the market is classified into:

  • Chronic Lymphocytic Leukemia (CLL)
  • Mantle Cell Lymphoma (MCL)
  • Waldenström’s Macroglobulinemia
  • Small Lymphocytic Lymphoma
  • Marginal Zone Lymphoma
  • Others

Based on distribution channel, the market is segmented into:

  • Hospital Based Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

On the basis of region, the market is categorised into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Trends

The key trends in the global Bruton’s Tyrosine Kinase (BTK) inhibitors market include growing requirements of treatments for lymphoma and leukaemia as the number of people suffering from these diseases increase at a rapid speed. With rapid rise in leukaemia and lymphoma cases and healthcare being easily accessible, BKT inhibitors can help meet the demands of cancer treatment.

Increasing novel drug launches as well as rising drug approvals are expected to fuel the growth of the Bruton’s tyrosine kinase inhibitors market. The increasing prevalence of chronic diseases coupled with rising disposable incomes is also expected to immensely contribute towards the global Bruton’s Tyrosine Kinase (BTK) inhibitors market growth. Collaboration of companies and academic professionals is further expected to contribute towards the development of BKT inhibitors.

In regional terms, North America accounts for a significant portion of the global Bruton’s tyrosine kinase (BTK) inhibitors market, owing to prevalence of chronic illnesses, improved healthcare infrastructure, and increased awareness. In the upcoming years the market in the Asia Pacific region is expected to grow at a rapid pace due to their improvements in healthcare infrastructure and developments in therapeutic and biotechnology research.

Key Market Players

The major players in the global Bruton’s tyrosine kinase (BTK) inhibitors market report are:

  • BeiGene, Ltd.
  • Merck KGaA
  • Principia Biopharma Inc.
  • ACEA Biosciences, Inc.
  • Bristol- Myers Squibb Company
  • Adolph Kiefer & Associates, Llc
  • Johnson & Johnson Services, Inc
  • ACEA Biosciences Inc.
  • Aptose Biosciences Inc. (APTO)
  • Eternity Bioscience Inc.
  • Takeda Pharmaceuticals Industries Ltd.
  • Gilead Sciences Inc.
  • AbbVie Inc.

The report covers the market shares, capacities, plant turnarounds, expansions, investments and mergers and acquisitions, among other latest developments of these market players.

Read More Reports:

Injection Moulding Machine Market:

Automotive Lightweight Material Market:

Automotive Pump Market:

Ventricular Assist Device Market:

Australia Lime Market:

About Us:

Expert Market Research (EMR) is leading market research company with clients across the globe. Through comprehensive data collection and skillful analysis and interpretation of data, the company offers its clients extensive, latest, and actionable market intelligence which enables them to make informed and intelligent decisions and strengthen their position in the market. The clientele ranges from Fortune 1000 companies to small and medium scale enterprises.

EMR customises syndicated reports according to clients’ requirements and expectations. The company is active across over 15 prominent industry domains, including food and beverages, chemicals and materials, technology and media, consumer goods, packaging, agriculture, and pharmaceuticals, among others.

Over 3000 EMR consultants and more than 100 analysts work very hard to ensure that clients get only the most updated, relevant, accurate and actionable industry intelligence so that they may formulate informed, effective and intelligent business strategies and ensure their leadership in the market.

Media Contact:

Company Name: Claight Corporation
Contact Person: Steven Luke, Corporate Sales Specialist – U.S.A.
Toll Free Number: +1-415-325-5166 | +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA


Post a Comment